График акции Kazia Therapeutics Limited
Расширенный график
Простой график
О компании Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.| IPO date | 1999-01-06 |
|---|---|
| ISIN | US48669G1058 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | aud |
| Див.доход ао | 26.59 |
| Дивиденд ао | 4.09 |
| Сайт | https://www.kaziatherapeutics.com |
| Цена ао | 0.9903 |
| Изменение цены за день: | -7.36% (0.95) |
|---|---|
| Изменение цены за неделю: | -9.82% (0.9759) |
| Изменение цены за месяц: | +407.85% (0.1733) |
| Изменение цены за 3 месяца: | +43.34% (0.614) |
| Изменение цены за полгода: | +2.34% (0.86) |
| Изменение цены за год: | +170.8% (0.325) |
| Изменение цены за 3 года: | -88.33% (7.54) |
| Изменение цены за 5 лет: | -78.69% (4.13) |
| Изменение цены с начала года: | -69.76% (2.91) |
|
|
Недооценка
|
Эффективность
|
|||||||||||||||||||||||||||||||||||||
Дивиденды
|
Долг
|
Импульс роста
|
|||||||||||||||||||||||||||||||||||||
| Институционалы | Объем | Доля, % |
|---|---|---|
| Armistice Capital, LLC | 2475555 | 10.47 |
| Platinum Investment Management Ltd | 1821887 | 7.71 |
| Morgan Stanley | 201550 | 0.85 |
| Bank of Montreal/Can/ | 140166 | 0.59 |
| HSBC Holdings PLC | 100194 | 0.42 |
| TWO SIGMA SECURITIES, LLC | 58423 | 0.25 |
| XTX Topco Ltd | 19436 | 0.08 |
| Acadian Asset Management. LLC | 18682 | 0.08 |
| Citadel Advisors Llc | 12809 | 0.05 |
| BNP Paribas Financial Markets | 12700 | 0.05 |
| Руководитель | Должность | Оплата | Год рождения |
|---|---|---|---|
| Ms. Anna Sandham | Company Secretary | N/A | |
| Dr. John Edwin Friend II, M.D. | CEO, MD & Director | 731.09k | 1970 (55 лет) |
| Ms. Gabrielle Heaton BBUS (ACC), CPA | Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer | 178.56k |
Адрес: Australia, Sydney, Three International Towers - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.kaziatherapeutics.com
Сайт: https://www.kaziatherapeutics.com
